Shanghai Fudan-zhangjiang Bio-pharmaceutical Co., Ltd.

This is a first-in-human study to test the safety and early effectiveness of a new cancer drug called FDA018-ADC in patients with advanced solid tumors that have spread. The main goals are to find the safest dose and see how the body processes the drug. The study includes patient…

This study is testing whether a new drug called FDA018-ADC works better than standard chemotherapy for people with advanced triple-negative breast cancer that has come back or stopped responding to a common type of chemotherapy. It will involve about 350 participants whose cancer…